From: Natalizumab in the pediatric MS population: results of the Italian registry
Clinical adverse events | Number of subjects |
---|---|
Headache | 13 |
Upper respiratory disorders | 9 |
Vertigo | 7 |
Gastrointestinal disorders | 5 |
Edema, itching, dermatitis | 6 |
Herpes zoster | 4 |
Restlessness | 2 |
Urinary tract infections | 3 |
Fatigue | 4 |
Infections | 2 |
Menstrual disorders | 2 |
Ovarian cyst | 1 |
Sacral cyst | 1 |
Muscular pain | 1 |
Weight loss | 3 |
Depression | 1 |
Hypertension | 1 |
Tachycardia | 1 |
Total | 66 |
Laboratory abnormalities | Number of subjects |
Increased white blood cells | 9 |
Increased bilirubin | 2 |
Increased ALT/AST | 2 |
Proteinuria | 1 |
Anemia | 1 |
Total | 15 |